Jeffrey Alan Barnes, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphoma, Large B-Cell, Diffuse | 4 | 2018 | 1378 | 0.810 |
Why?
|
| Lymphoma, B-Cell | 4 | 2019 | 931 | 0.770 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 9 | 2023 | 11524 | 0.540 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 2 | 2016 | 166 | 0.460 |
Why?
|
| Lymph Nodes | 2 | 2014 | 3474 | 0.420 |
Why?
|
| Neurotoxicity Syndromes | 2 | 2023 | 290 | 0.300 |
Why?
|
| Hodgkin Disease | 3 | 2023 | 1415 | 0.300 |
Why?
|
| Doxorubicin | 5 | 2023 | 2234 | 0.250 |
Why?
|
| Neutropenia | 2 | 2023 | 895 | 0.230 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 4 | 2013 | 693 | 0.220 |
Why?
|
| Immunotherapy, Adoptive | 3 | 2023 | 1270 | 0.220 |
Why?
|
| Vinblastine | 2 | 2023 | 502 | 0.200 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2022 | 1596 | 0.190 |
Why?
|
| Dacarbazine | 2 | 2023 | 566 | 0.180 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2023 | 895 | 0.180 |
Why?
|
| Cysts | 1 | 2022 | 678 | 0.150 |
Why?
|
| Antigens, CD19 | 1 | 2019 | 380 | 0.140 |
Why?
|
| Vincristine | 3 | 2013 | 1039 | 0.140 |
Why?
|
| Disease-Free Survival | 3 | 2018 | 6895 | 0.140 |
Why?
|
| Human T-lymphotropic virus 1 | 1 | 2016 | 140 | 0.130 |
Why?
|
| Hydroxamic Acids | 1 | 2018 | 494 | 0.130 |
Why?
|
| Lymphatic Diseases | 2 | 2013 | 324 | 0.130 |
Why?
|
| Lymphoma | 1 | 2023 | 1877 | 0.120 |
Why?
|
| Prednisone | 3 | 2013 | 1574 | 0.120 |
Why?
|
| Jaw | 1 | 2013 | 96 | 0.110 |
Why?
|
| Arabinonucleosides | 1 | 2013 | 35 | 0.110 |
Why?
|
| Cyclophosphamide | 3 | 2013 | 2242 | 0.110 |
Why?
|
| Adenine Nucleotides | 1 | 2013 | 121 | 0.110 |
Why?
|
| Sezary Syndrome | 1 | 2013 | 76 | 0.110 |
Why?
|
| Hematuria | 1 | 2013 | 235 | 0.110 |
Why?
|
| Lung Diseases | 1 | 2022 | 1886 | 0.100 |
Why?
|
| Fatal Outcome | 2 | 2013 | 1850 | 0.100 |
Why?
|
| Stem Cell Transplantation | 2 | 2018 | 1620 | 0.100 |
Why?
|
| Confusion | 1 | 2013 | 275 | 0.100 |
Why?
|
| Skin | 2 | 2016 | 4364 | 0.100 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2015 | 547 | 0.100 |
Why?
|
| Hypercalcemia | 1 | 2013 | 409 | 0.100 |
Why?
|
| Deltaretrovirus Antibodies | 1 | 2009 | 9 | 0.090 |
Why?
|
| Recurrence | 3 | 2018 | 8340 | 0.090 |
Why?
|
| Diagnosis, Differential | 4 | 2016 | 12959 | 0.090 |
Why?
|
| Radiography, Abdominal | 1 | 2013 | 537 | 0.090 |
Why?
|
| Remission Induction | 2 | 2013 | 2386 | 0.090 |
Why?
|
| Mediastinal Neoplasms | 1 | 2013 | 423 | 0.090 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2019 | 1381 | 0.090 |
Why?
|
| Indoles | 1 | 2018 | 1839 | 0.090 |
Why?
|
| Anti-Retroviral Agents | 1 | 2019 | 1715 | 0.090 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2013 | 640 | 0.080 |
Why?
|
| Life Expectancy | 1 | 2015 | 1184 | 0.080 |
Why?
|
| Administration, Oral | 2 | 2013 | 3913 | 0.080 |
Why?
|
| Drug Administration Schedule | 2 | 2012 | 4933 | 0.070 |
Why?
|
| Urinary Bladder | 1 | 2013 | 1172 | 0.070 |
Why?
|
| Male | 15 | 2021 | 350118 | 0.070 |
Why?
|
| Bone Marrow | 2 | 2013 | 2948 | 0.070 |
Why?
|
| Aged | 11 | 2021 | 163280 | 0.070 |
Why?
|
| Suprachiasmatic Nucleus | 2 | 2004 | 147 | 0.070 |
Why?
|
| Survival Analysis | 2 | 2019 | 10252 | 0.070 |
Why?
|
| Fatigue | 1 | 2012 | 1531 | 0.060 |
Why?
|
| Sirolimus | 1 | 2012 | 1564 | 0.060 |
Why?
|
| Biological Clocks | 2 | 2004 | 321 | 0.060 |
Why?
|
| Cyclic GMP-Dependent Protein Kinases | 1 | 2004 | 30 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2022 | 20129 | 0.060 |
Why?
|
| Photoreceptor Cells, Invertebrate | 1 | 2003 | 39 | 0.060 |
Why?
|
| Humans | 21 | 2023 | 744343 | 0.060 |
Why?
|
| Methotrexate | 1 | 2010 | 1727 | 0.060 |
Why?
|
| Aged, 80 and over | 4 | 2018 | 57776 | 0.060 |
Why?
|
| Middle Aged | 11 | 2022 | 213383 | 0.060 |
Why?
|
| Emigrants and Immigrants | 1 | 2009 | 522 | 0.060 |
Why?
|
| Anemia | 1 | 2012 | 1506 | 0.060 |
Why?
|
| Female | 13 | 2022 | 380194 | 0.050 |
Why?
|
| Adult | 9 | 2022 | 214055 | 0.050 |
Why?
|
| Circadian Rhythm | 2 | 2004 | 2624 | 0.050 |
Why?
|
| Bleomycin | 1 | 2023 | 512 | 0.050 |
Why?
|
| Pruritus | 2 | 2016 | 361 | 0.050 |
Why?
|
| Transplantation, Homologous | 1 | 2009 | 4776 | 0.050 |
Why?
|
| Models, Statistical | 1 | 2015 | 5102 | 0.050 |
Why?
|
| Eye Proteins | 1 | 2003 | 646 | 0.040 |
Why?
|
| Pain | 1 | 2013 | 4986 | 0.040 |
Why?
|
| Treatment Outcome | 5 | 2019 | 63114 | 0.040 |
Why?
|
| Neoplasm, Residual | 1 | 2021 | 973 | 0.040 |
Why?
|
| Central Nervous System | 1 | 2023 | 1357 | 0.030 |
Why?
|
| Leg Injuries | 1 | 2016 | 178 | 0.030 |
Why?
|
| Drosophila Proteins | 1 | 2003 | 1703 | 0.030 |
Why?
|
| Mastocytosis | 1 | 2016 | 160 | 0.030 |
Why?
|
| Skin Neoplasms | 1 | 2013 | 5686 | 0.030 |
Why?
|
| Dermatitis, Exfoliative | 1 | 2013 | 28 | 0.030 |
Why?
|
| Piperidines | 1 | 2021 | 1602 | 0.030 |
Why?
|
| Sarcoma, Kaposi | 1 | 2016 | 370 | 0.030 |
Why?
|
| HIV Infections | 1 | 2019 | 16718 | 0.030 |
Why?
|
| Hypereosinophilic Syndrome | 1 | 2013 | 93 | 0.030 |
Why?
|
| Antibodies, Neutralizing | 1 | 2022 | 1978 | 0.030 |
Why?
|
| Sulfonamides | 1 | 2021 | 1938 | 0.030 |
Why?
|
| C-Reactive Protein | 1 | 2023 | 3778 | 0.030 |
Why?
|
| Markov Chains | 1 | 2015 | 969 | 0.030 |
Why?
|
| Oligonucleotides, Antisense | 2 | 2004 | 433 | 0.030 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2009 | 5442 | 0.030 |
Why?
|
| Exanthema | 1 | 2016 | 501 | 0.020 |
Why?
|
| Pyrazoles | 1 | 2021 | 1972 | 0.020 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2019 | 1873 | 0.020 |
Why?
|
| Prostatic Neoplasms | 1 | 2013 | 11124 | 0.020 |
Why?
|
| Young Adult | 4 | 2019 | 56430 | 0.020 |
Why?
|
| Biological Products | 1 | 2019 | 860 | 0.020 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 1519 | 0.020 |
Why?
|
| Neoplasm Staging | 2 | 2015 | 11031 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2021 | 2942 | 0.020 |
Why?
|
| Causality | 1 | 2015 | 1275 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2010 | 1420 | 0.020 |
Why?
|
| Disease Management | 1 | 2019 | 2459 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2013 | 2618 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2013 | 1915 | 0.020 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2013 | 2559 | 0.020 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2019 | 2214 | 0.020 |
Why?
|
| Dermatitis, Atopic | 1 | 2013 | 654 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2023 | 10180 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2015 | 2616 | 0.020 |
Why?
|
| Flavoproteins | 1 | 2003 | 43 | 0.010 |
Why?
|
| Cryptochromes | 1 | 2003 | 45 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2003 | 12208 | 0.010 |
Why?
|
| Kidney Failure, Chronic | 1 | 2016 | 2538 | 0.010 |
Why?
|
| Period Circadian Proteins | 1 | 2003 | 102 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 2019 | 4253 | 0.010 |
Why?
|
| Rats, Inbred Lew | 1 | 2004 | 1162 | 0.010 |
Why?
|
| NIH 3T3 Cells | 1 | 2004 | 677 | 0.010 |
Why?
|
| Rats, Inbred Strains | 1 | 2003 | 2186 | 0.010 |
Why?
|
| Boston | 1 | 2015 | 9313 | 0.010 |
Why?
|
| United States | 1 | 2009 | 69872 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2015 | 6196 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2023 | 77449 | 0.010 |
Why?
|
| Comorbidity | 1 | 2015 | 10388 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2015 | 12354 | 0.010 |
Why?
|
| Electrophysiology | 1 | 2003 | 1308 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2015 | 14722 | 0.010 |
Why?
|
| RNA, Messenger | 2 | 2004 | 13033 | 0.010 |
Why?
|
| Risk | 1 | 2010 | 9687 | 0.010 |
Why?
|
| Rats | 2 | 2004 | 24260 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2022 | 53288 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 19905 | 0.010 |
Why?
|
| Incidence | 1 | 2015 | 20947 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2019 | 40561 | 0.010 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2003 | 1222 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2003 | 4751 | 0.010 |
Why?
|
| Transfection | 1 | 2003 | 5892 | 0.010 |
Why?
|
| RNA Interference | 1 | 2003 | 2889 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2015 | 23338 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2010 | 9274 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2003 | 2915 | 0.010 |
Why?
|
| Cell Cycle Proteins | 1 | 2003 | 3462 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2013 | 39050 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2013 | 13695 | 0.010 |
Why?
|
| Cell Line | 1 | 2003 | 15997 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2003 | 5853 | 0.010 |
Why?
|
| Neurons | 1 | 2003 | 9338 | 0.000 |
Why?
|
| Time Factors | 1 | 2004 | 40075 | 0.000 |
Why?
|
| Animals | 2 | 2004 | 168757 | 0.000 |
Why?
|
| Mice | 1 | 2004 | 81183 | 0.000 |
Why?
|